BAX
Baxter International Inc.
BAX has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BAX overall, supported by stronger fundamentals and stronger modeled upside.
BAX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Unavailable | |
| Strong |
BAX's balance sheet is currently strong, and its revenue is stable, but its profitability is under pressure. There isn't enough data to rate its cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BAX PE Valuation
BAX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BAX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAX, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BAX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.06 | — |
| Q3 2026 | -$1.43 | -$0.77 |
| Q2 2026 | -$2.09 | -$1.79 |
| Q1 2026 | -$2.15 | -$1.05 |
| Q4 2025 | -$1.87 | -$0.59 |
| Q3 2025 | -$0.66 | -430% |
| Q2 2025 | -$0.30 | -106% |
| Q1 2025 | -$1.10 | -121% |
| Q4 2024 | -$1.28 | -125% |
BAX is still losing money, but far less than before: $1.43 per share over the past year, against $5.66 at its worst in mid-2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BAX on earnings quality, reporting a profit while its opponent remains loss making.
BAX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3B | +5% |
| Q2 2026 | $3B | +5.3% |
| Q1 2026 | $2.7B | +2.9% |
| Q4 2025 | $3B | +8% |
| Q3 2025 | $2.8B | +5% |
| Q2 2025 | $2.8B | -26% |
| Q1 2025 | $2.6B | -27% |
| Q4 2024 | $2.8B | -29% |
BAX's revenue has grown year over year for five quarters in a row: $3B last quarter, up 5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.6% | +1.5 points |
| Q2 2026 | 7.3% | +0.5 points |
| Q1 2026 | 2.4% | +0.2 points |
| Q4 2025 | -25% | -8.7 points |
| Q3 2025 | 6.1% | +0.3 points |
| Q2 2025 | 6.8% | +12 points |
| Q1 2025 | 2.2% | -3 points |
| Q4 2024 | -16% | -24 points |
BAX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BAX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BAX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $558M | +135% |
| Q2 2026 | $285M | +31% |
| Q1 2026 | $213M | +$406M |
| Q3 2025 | $237M | -6.3% |
| Q2 2025 | $217M | +89% |
| Q1 2025 | -$193M | -218% |
| Q3 2024 | $253M | +32% |
| Q2 2024 | $115M | -41% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with BAX at up 38%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
BAX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +2M shares |
| 1 year | +1.2% | +6M shares |
| 3 years | +2.2% | +11M shares |
| 5 years | +2.8% | +14M shares |
| Available history | +0.2% | +1M shares |
BAX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q4 2022 | — |
| Q3 2022 | $32M |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | $35M |
| Q2 2021 | $312M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BAX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
| Q2 2026 | -1.9x | Net Cash |
| Q1 2026 | -1.8x | Net Cash |
| Q4 2025 | 11.2x | High |
| Q3 2025 | -1.0x | Net Cash |
| Q2 2025 | -2.0x | Net Cash |
| Q1 2025 | -3.3x | Net Cash |
| Q4 2024 | 16.0x | High |
BAX has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over BAX on leverage, with a lower net debt burden relative to earnings.
BAX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.5 | Neutral |
| Stochastic | 40.5 | Neutral |
BAX's weekly RSI is 59 (neutral) and its Stochastic is 40 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BAX PE vs Healthcare Sector
| Metric | BAX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BAX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BAX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $24.5 | 4.9% above |
| 20 week MA | $24.6 | 4.6% above |
| 50 week MA | $21.3 | 21% above |
| 100 week MA | $24.5 | 5.1% above |
| 200 week MA | $31.7 | 19% below |
BAX has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 19% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BAX on trend strength, trading above more of its moving averages.
BAX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $84.1 | $79.6 | -5.3% |
| 2021 | $79.6 | $85.6 | +7.5% |
| 2022 | $85.6 | $50.2 | -41% |
| 2023 | $50.2 | $38.7 | -23% |
| 2024 | $38.7 | $29.2 | -24% |
| 2025 | $29.2 | $19.4 | -34% |
| 2026 YTD | $19.4 | $25.7 | +33% |
BAX has finished four years in a row lower, and it's up 33% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BAX on returns for 2026, with the stronger performance.